This retrospective study was conducted in Japan to determine the incidence, risk factors and outcomes of sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic stem cell transplantation (HSCT). Among 4290 patients undergoing allogeneic HSCT between 1999 and 2010, 462 were diagnosed with SOS according to the Seattle criteria (cumulative incidence, 10.8%). The cumulative incidence of SOS diagnosed by the modified Seattle criteria was 9.3%. Of 462 patients, 107 met the Baltimore criteria and 168 had severe SOS with renal and/or respiratory failure. The median onset for SOS was 12 days after HSCT (range, À 2-30). Overall survival at day 100 was 32% for SOS and 15% for severe SOS. Multivariate analyses showed that significant independent risk factors for SOS were the number of HSCTs, age, performance status, hepatitis C virus-seropositivity, advanced disease status and myeloablative regimen. SOS was highly associated with overall mortality (hazard ratio, 2.09; P o 0.001). Our retrospective survey showed that the cumulative incidence of SOS in Japan was 10.8%, similar to that previously reported in Western countries, and that the overall survival of patients who developed SOS was low. Furthermore, several risk factors were identified. Preventive and therapeutic strategies for high-risk SOS patients must be established to improve overall survival.
INTRODUCTION
Recently, many changes have been made to improve the outcomes of hematopoietic stem cell transplantation (HSCT), including improvements in conditioning regimen, donor selection and prophylaxis, and in the treatment of organ complications, GVHD and infection. Although HSCT outcomes are gradually improving, they are still unsatisfactory. [1] [2] [3] [4] [5] Sinusoidal obstruction syndrome (SOS) is a well-known, potentially lethal complication of HSCT. Its reported incidence ranges from 5% to over 50%. [6] [7] [8] [9] This variability in SOS incidence may result from the use of different diagnostic criteria. SOS usually occurs within the first 3 weeks after HSCT as a result of endothelial and hepatic damage caused by the conditioning regimen. 10 Because SOS is associated with low platelet count and ascites, it is usually diagnosed by clinical manifestations rather than liver biopsy. Painful hepatomegaly, jaundice, ascites and unexplained weight gain are the primary symptoms of SOS. Two major clinical diagnostic systems, proposed by groups in Seattle and Baltimore, are currently used. [6] [7] [8] Recent retrospective studies reported the incidence of SOS, according to the Seattle criteria, as 17.3 and 13.8%. 11, 12 SOS has a poor prognosis. Although patients with mild SOS improved with supportive care alone, the overall mortality in patients with severe SOS was 84.3%. 11 There are no satisfactory drugs for prophylaxis and treatment of SOS, aside from defibrotide. [13] [14] [15] [16] [17] Thus, SOS remains a critical problem following HSCT. 18 Several studies from Western countries have reported the incidence of SOS in large patient samples, but none exist from Asian countries. To determine the incidence, risk factors and outcomes of clinically diagnosed SOS after allogeneic HSCT, we conducted a retrospective study among centers registered with the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
retrospectively analyzed. Patient data were based on the Japan transplant outcomes registry database by the Transplant Registry Unified Management Program (TRUMP), confirmed in 2010. 19 Additional data were collected regarding clinical presentation, diagnosis, treatment and follow-up of 618 cases that developed SOS. Treatment totals could exceed 100% because patients could have received multiple treatments. This study was approved by the institutional review boards of the National Cancer Center Hospital, Kobe University Hospital and the JSHCT.
Definitions of SOS
The diagnosis of SOS was established clinically, based on the Seattle or Baltimore criteria. The Seattle criteria include the presence of at least two of the following, occurring within 30 days after HSCT: (i) jaundice, (ii) hepatomegaly and right upper-quadrant pain and (iii) ascites and/or unexplained weight gain (⩾2%). 6 The modified Seattle criteria include the presence of at least two of the following within 20 days after HSCT: (i) hyperbilirubinemia ⩾ 2 mg/dL, (ii) hepatomegaly or right upperquadrant pain of liver origin and (iii) sudden weight gain (⩾2%). 7 The Baltimore criteria include the development of hyperbilirubinemia ⩾ 2 mg/dL within 21 days after HSCT and at least two of the following: (i) hepatomegaly, (ii) ascites and (iii) weight gain (⩾5%). 8 Severe SOS was defined as SOS with renal failure (serum creatinine ⩾ 3 × the upper limit of normal or dialysis dependency) and/or respiratory failure (oxygen saturation o90% in room air, requirement for oxygen supplementation or ventilator dependency) at diagnosis. Non-severe SOS was defined as SOS without renal or respiratory failure. A complete response (CR) for SOS was defined as the resolution of all signs and symptoms of the SOS diagnostic criteria.
Statistical analysis
Categorical and continuous variables were compared using chi-squared tests and Student's t-tests, respectively. The cumulative incidence of SOS was estimated by cumulative incidence functions, considering non-SOS death within 30 days after HSCT as a competing risk. Overall survival was estimated by the Kaplan-Meier method, with SOS treated as a timedependent variable, and compared using the log-rank test.
In the multivariate analyses, the Fine and Gray's model was used to identify risk factors for SOS development, and the Cox proportional hazard model was used to examine the effect of SOS on overall mortality, treating SOS as a time-dependent covariate. The variables considered were: the number of transplantations; patient's age at transplantation (⩽15 years, 16-39 years and ⩾ 40 years); patient's sex; donor-patient sex mismatch (matched male to female vs female to male); Eastern Cooperative Oncology Group (ECOG) performance status (PS; 0 or 1 vs 2-4); hepatitis B virus serostatus; hepatitis C virus (HCV) serostatus; disease status at conditioning (grouped as (i) standard risk disease: first or second CR of AML, first CR of ALL, first chronic phase of CML and refractory anemia or refractory anemia with ringed sideroblasts; vs (ii) advanced disease for all other AML, ALL, CML and myelodysplastic syndrome; vs (iii) other hematological malignancies; vs (iv) bone marrow failure, including aplastic anemia); the conditioning regimen (reduced-intensity conditioning vs myeloablative conditioning (MAC)) and the type of prophylaxis against GVHD (tacrolimus-based vs cyclosporine-based). Conditioning regimens were classified as myeloablative if TBI 48 Gy, oral busulfan (Bu) ⩾ 9 mg/kg, IV Bu ⩾ 7.2 mg/kg or melphalan 4140 mg/m 2 was used (based on reports from the Center for International Blood and Marrow Transplant Research). 20, 21 SOS was maintained in the model. Other variables with P-values o0.1 were selected for the model, and were finally selected in a backward stepwise manner with a variable retention criterion of Po0.05. Statistical significance was defined as a two-tailed P-value o0.05. Statistical analyses were performed using Stata version 12 (StataCorp, College Station, TX, USA).
RESULTS

Patient characteristics
Characteristics of the 4290 patients who underwent HSCT are shown in Table 1 , and characteristics of the SOS patients are detailed in Table 2 . Overall, 747 patients received two or more transplantations. Of these, the previous HSCTs were allogeneic (n = 538), autologous (n = 188), syngeneic (n = 4) and unknown (n = 17). As some patients underwent previous transplantation before our study period, the total number of transplantations included was 4290. The median age of the SOS patients was 43 years (range, 0-72); 346 patients (75%) received MAC and 108 (23%) reduced-intensity conditioning. Abbreviations: ATL = adult T-cell leukemia; BM = bone marrow; Bu = busulfan; CB = cord blood; CSP = cyclosporine; CY = cyclophosphamide; ECOG = Eastern Cooperative Oncology Group; Flu = fludarabine; HBV = hepatitis B virus; HCV = hepatitis C virus; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; Mel = melphalan; MPD = myeloproliferative disease; PB = peripheral blood; PS = performance status; RIC = reduced-intensity conditioning; TAC = tacrolimus.
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Clinical presentation of SOS Among 618 patients, 156 did not meet the SOS criteria described above. The clinical diagnosis of SOS was based on the Seattle criteria (cumulative incidence, 10.8%; 95% confidence interval (CI), 9.9-11.7); 107 of the 462 patients also met the Baltimore criteria. 
SOS treatment
Questionnaire results revealed that attending physicians used the following therapeutic agents: fresh frozen plasma (37%), ursodeoxycholic acid (37%), antithrombin III (33%), low MW heparin (29%), prostaglandin E1 (16%), heparin (13%), recombinant thrombomodulin (12%), tissue plasminogen activator (10%) and others. Defibrotide, which was not approved in Japan, was used in only 5% of patients.
Response to SOS treatment Table 5 shows the CR rate for SOS. Overall, the SOS CR rate was 45%, but it was lower in those who fulfilled both the Seattle and Baltimore criteria at diagnosis (23%; P o 0.001). In patients with severe SOS, the CR rate among those fulfilling both criteria was only 10%.
Overall survival The median follow-up period for survivors was 1357 days (range, 2-4870). In SOS patients, survival at day 100 was 32%; in patients without SOS, it was 76% (P o 0.001; Figure 1a ). Patients meeting both the Seattle and Baltimore criteria (n = 107) had a poor prognosis (Figure 1b ). Overall survival at day 100 was only 15% for those fulfilling both criteria at the time of SOS diagnosis. Overall survival was significantly lower for patients with severe SOS than for those with non-severe SOS. Overall survival at day 100 was 44% for non-severe (n = 294) and 15% for severe SOS (n = 168) (P o 0.001; Figure 1c) .
We divided the patients into four groups according to their condition at SOS diagnosis: (i) non-severe SOS patients diagnosed by the Seattle criteria alone ('Non-severe SOS, Seattle'; n = 245), (ii) non-severe SOS patients who fulfilled both criteria ('Non-severe SOS, Baltimore'; n = 49), (iii) severe SOS patients diagnosed by the Abbreviations: ATL = adult T-cell leukemia; BM = bone marrow; Bu = busulfan; CB = cord blood; CSP = cyclosporine; CY = cyclophosphamide; ECOG = Eastern Cooperative Oncology Group; Flu = fludarabine; HBV = hepatitis B virus; HCV = hepatitis C virus; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; Mel = melphalan; MPD = myeloproliferative disease; PB = peripheral blood; PS = performance status; RIC = reducedintensity conditioning; SOS = sinusoidal obstruction syndrome; TAC = tacrolimus.
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Seattle criteria alone ('Severe SOS, Seattle'; n = 110) and (iv) severe SOS patients who fulfilled both criteria ('Severe SOS, Baltimore'; n = 58). Overall survival at day 100 in the four groups was 47%, 28%, 21% and 5%, respectively. The prognoses of the four groups were significantly different (P o0.001, Figure 1d ). 'Non-severe SOS, Seattle' patients had the best prognosis and 'Severe SOS, Baltimore' patients had the worst prognosis.
The main causes of death in all SOS patients were SOS-related mortality (49%) and disease progression (18%). The proportion of patients who died of SOS-related causes was significantly higher in severe SOS than in non-severe SOS (61% vs 41%, P o0.001).
Multivariate analyses for mortality
The multivariate model, adjusted for other significant variables affecting survival, revealed that SOS was highly associated with overall mortality (hazard ratio, 2.09; 95% CI, 1.84-2.36; P o0.001).
DISCUSSION
Here, the incidence of SOS in Japan was 10.8%, similar to that reported in Western countries. 11, 12 While the reported incidence of acute GVHD is lower in Japanese than in Caucasian patients, 22 ethnicity was not associated with SOS incidence. Coppell et al.
11
reported that the overall incidence of SOS has increased because of transplantation diversity. However, Carreras et al. 12 reported a decrease because of the introduction of reduced-intensity conditioning and improvement of MAC procedures using alternative donors. We did not detect a change in SOS incidence over time.
We focused on patients clinically diagnosed with SOS using representative criteria (the Seattle and Baltimore criteria 6, 8 ), because liver biopsy is difficult to conduct and SOS diagnosis is usually made on the basis of such clinical diagnostic criteria. However, the clinical findings of SOS are not specific, and physicians must differentiate SOS from other diagnoses, such as cholangitis lenta, infectious liver disease, acute GVHD or drug toxicity. 23 Although our retrospective study did not include biomarker analyses, some are thought to be useful for diagnosing Abbreviations: Bu = busulfan; CI = confidence interval; HCV = hepatitis C virus; HSCT = hematopoietic stem cell transplantation; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; RIC = reducedintensity conditioning; SOS = sinusoidal obstruction syndrome. Table 5 . Sinusoidal obstruction syndrome after transplant K Yakushijin et al SOS. Recent research has identified plasminogen activator inhibitor type 1, 24 procollagen type III, 25 antithrombin and protein C 26 as potential biomarker candidates for SOS. However, none appears to be SOS-specific. Further research is required to detect specific SOS biomarkers.
In our study, the number of HSCTs, age, poor PS and MAC regimen, especially Bu-containing regimens, were risk factors for SOS, as previously reported. 7, 9, 12, 18, 27, 28 Contrary to previous reports, patients receiving oral Bu here had a relatively lower risk of SOS development than did patients receiving IV Bu. We think this difference is because: (i) this was a retrospective study, which contains biases, and (ii) we do not routinely adjust Bu dose after monitoring the drug concentration. The RR of SOS in patients aged ⩾ 40 years was similar to that in patients aged 0-15 years, but it was lower for those between 16 and 39 years of age. Our study also indicated that disease status and HCV infection were associated with an increased risk of SOS. Although we recently reported the impact of HCV infection on clinical outcomes in HSCT recipients, various criteria for SOS diagnosis were used by the attending physicians. 29 In this study, SOS diagnosis was based on the Seattle criteria and verified by collecting additional data from 117 centers. Although the number of HCV-seropositive patients was small, multivariate analyses confirmed HCV-positivity as an independent risk factor for SOS. Pretransplantation liver disease is also a major reported risk factor. 7, 9, 12, 18, 28 Because information on pretransplantation comorbidities was only recently added to the TRUMP database, we did not investigate pretransplant liver disease, to avoid bias. Use of gemtuzumab ozogamicin is also a risk factor for SOS. 18, 28, 30, 31 However, we do not have data on gemtuzumab ozogamicin use, as it is rarely used before transplantation in Japan.
The overall CR rate was 45%. The CR rate of patients diagnosed by both the Seattle and the Baltimore criteria was only 23%. Richardson et al. 15 reported that the CR rate for SOS diagnosed by the Baltimore criteria and treated with defibrotide was 46%. For patients with severe SOS fulfilling the Baltimore criteria at diagnosis, the CR rate was extremely low (10%) in our cohort, similar to that for historical controls without defibrotide treatment. 11 However, the CR rate was 19-29% among patients with renal and/or respiratory failure treated with defibrotide, 15 suggesting that defibrotide might prevent SOS progression and improve clinical outcomes.
In Japan, defibrotide is not available, except for compassionate use or clinical trials, 32 even though it is the only agent recommended for SOS prophylaxis and treatment by the BCSH/ BSBMT guidelines. 28 No SOS patients in our cohort received Figure 1 . The probabilities of overall survival. Overall survival in patients with SOS following HSCT was significantly lower than that in patients who underwent HSCT but did not develop SOS (a). Overall survival in SOS patients who fulfilled both the Baltimore and Seattle criteria at diagnosis was very low (b). Overall survival in severe SOS patients was significantly lower than that in non-severe SOS patients (c). When SOS patients were divided into four groups according to their condition at the time of SOS diagnosis, (i) 'Non-severe SOS, Seattle' (non-severe SOS patients diagnosed by the Seattle criteria alone), (ii) 'Non-severe SOS, Baltimore' (non-severe SOS patients who fulfilled both the Baltimore and Seattle criteria at diagnosis), (iii) 'Severe SOS, Seattle' (severe SOS patients diagnosed by the Seattle criteria alone) and (iv) 'Severe SOS, Baltimore' (severe SOS patients who fulfilled both the Baltimore and Seattle criteria at diagnosis), the prognoses of the four groups were significantly different (d). *Patients who were diagnosed with SOS by the Seattle criteria but did not fulfill the Baltimore criteria at diagnosis. **Patients who fulfilled both the Baltimore and Seattle criteria at diagnosis.
defibrotide for SOS prophylaxis. Recombinant thrombomodulin is approved and widely used to treat disseminated intravascular coagulation in Japan. Recent reports suggest that thrombomodulin is efficacious for SOS treatment, 33, 34 but it might be associated with intracranial hemorrhage. 35 Although thrombomodulin may be a reasonable alternative SOS treatment, this should be confirmed by a prospective study.
We divided the patients in our study into four groups according to SOS severity and diagnostic criteria. We found that overall survival was significantly different among the four groups (Figure 1d) . Patients in the 'Non-severe SOS, Seattle' group had the best prognosis, while those in 'Severe SOS, Baltimore' group had the worst prognosis. This classification might be a useful system for grading disease severity and prognosis upon diagnosis of SOS. Multiorgan failure has been used to prospectively define the severity of SOS in clinical studies using defibrotide therapy. 15 The Baltimore criteria are more stringent than the Seattle criteria, and the mortality rate due to SOS among patients diagnosed using the Baltimore criteria is high. 12 Thus, our classification into these four groups is reasonable. Several grading systems have been reported. 7,9,36,37 Chao 36 proposed an alternative grading system based on bilirubin levels and liver function test results, as well as rate of change, amount and pace of weight gain, presence of hepatomegaly and overall symptoms. Recently, Carreras 37 proposed a modified grading system and practical treatment strategies according to the grade. Although our database did not include the rate and the pace of clinical changes, renal and/or respiratory failure and meeting the Baltimore criteria suggest rapid deterioration of SOS.
This study has several limitations because of its retrospective nature. First, patient background data, including details of SOS prophylaxis, history of pretransplantation liver injury, antibiotic use and prior abdominal irradiation, were not available. Second, the presence of SOS was based on the records of patients clinically diagnosed by attending physicians rather than by a central review panel. However, our results are validated by the large number of patients included in this study, as it was the largest nationwide survey of SOS in an Asian country.
In conclusion, this retrospective survey showed that the cumulative incidence of SOS in the Japanese population was 10.8%, similar to previous reports from Western countries. 11, 12 Overall survival of these patients was quite low, and was lowest in patients with severe SOS. Preventive and therapeutic strategies for high-risk SOS patients must be established to improve overall survival.
